个人信息
姓名：郭军
学历：博士
职称：教授
E-mail：jguo@ccnu.edu.cn
教育与研究经历
1990-1994 武汉大学，化学学士
1994-1997 中国科学院福建物质结构研究所，物理化学硕士
1998-2002 英国谢菲尔德大学，有机化学博士
2002-2011 英国杜伦大学及美国佐治亚大学，博士后及研究专职
研究领域与兴趣
1. 抗肿瘤疫苗或抗病原体疫苗的设计、制备及免疫性质评估
2. 用于免疫治疗的生物大分子及化学小分子合成、修饰和性质
承担项目与课题信息
国家自然科学基金、科技部等项目课题
学术成果（代表性论文）
(1) MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern. J. Med. Chem. 2022, 65, 3563-3574.
(2) Self-Adjuvanting Lipoprotein Conjugate alphaGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern. J. Med. Chem. 2022, 65, 2558–2570.
(3) Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine. Front. Immunol. 2022, 13, 857779.
(4) A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern. Chem. Commun. 2022, 58, 3925-3928.
(5) RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern. Chem. Commun. 2022, 58, 2120-2123.
(6) MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide. Front. Chem. 2022, 10, 814880.
(7) Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern. ACS Infect Dis. 2022, 8, 1367-1375.
